Bromodomain-selective BET inhibitors are potent antitumor agents against MYC-driven pediatric cancer

P. Jake Slavish, Liying Chi, Mi Kyung Yun, Lyudmila Tsurkan, Nancy E. Martinez, Barbara Jonchere, Sergio C. Chai, Michele Connelly, M. Brett Waddell, Sourav Das, Geoffrey Neale, Zhenmei Li, William R. Shadrick, Rachelle R. Olsen, Kevin W. Freeman, Jonathan A. Low, Jeanine E. Price, Brandon M. Young, Nagakumar Bharatham, Vincent A. BoydJun Yang, Richard E. Lee, Marie Morfouace, Martine F. Roussel, Taosheng Chen, Daniel Savic, R. Kiplin Guy, Stephen W. White, Anang A. Shelat, Philip M. Potter

Research output: Contribution to journalArticlepeer-review

31 Scopus citations

Fingerprint

Dive into the research topics of 'Bromodomain-selective BET inhibitors are potent antitumor agents against MYC-driven pediatric cancer'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science

Biochemistry, Genetics and Molecular Biology